Drug Profile


Alternative Names: MP 1727; OctreoScan; SomatoTher

Latest Information Update: 24 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Bristol-Myers Squibb; Louisiana State University; Novartis
  • Class Cyclic peptides; Radiopharmaceutical diagnostics; Somatostatins
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuroendocrine tumours

Most Recent Events

  • 10 Dec 2001 Launched for Neuroendocrine tumour diagnosis in Canada (IV)
  • 01 Nov 2000 Mallinckrodt has been acquired by Tyco International
  • 29 May 2000 DuPont Pharmaceuticals has exclusive distribution rights in Canada for pentetreotide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top